<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:35:03Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8843217" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8843217</identifier>
        <datestamp>2022-02-15</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS One</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8843217</article-id>
              <article-id pub-id-type="pmcid">PMC8843217</article-id>
              <article-id pub-id-type="pmc-uid">8843217</article-id>
              <article-id pub-id-type="pmid">35157713</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0262111</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-21-21069</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Diagnostic Medicine</subject>
                    <subj-group>
                      <subject>Diagnostic Radiology</subject>
                      <subj-group>
                        <subject>Tomography</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Research and Analysis Methods</subject>
                  <subj-group>
                    <subject>Imaging Techniques</subject>
                    <subj-group>
                      <subject>Diagnostic Radiology</subject>
                      <subj-group>
                        <subject>Tomography</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Radiology and Imaging</subject>
                    <subj-group>
                      <subject>Diagnostic Radiology</subject>
                      <subj-group>
                        <subject>Tomography</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Computer and Information Sciences</subject>
                  <subj-group>
                    <subject>Artificial Intelligence</subject>
                    <subj-group>
                      <subject>Machine Learning</subject>
                      <subj-group>
                        <subject>Deep Learning</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Head</subject>
                      <subj-group>
                        <subject>Eyes</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Head</subject>
                      <subj-group>
                        <subject>Eyes</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Ocular System</subject>
                      <subj-group>
                        <subject>Eyes</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Ocular System</subject>
                      <subj-group>
                        <subject>Eyes</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Neuroscience</subject>
                    <subj-group>
                      <subject>Cognitive Science</subject>
                      <subj-group>
                        <subject>Cognitive Psychology</subject>
                        <subj-group>
                          <subject>Perception</subject>
                          <subj-group>
                            <subject>Sensory Perception</subject>
                            <subj-group>
                              <subject>Vision</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Psychology</subject>
                    <subj-group>
                      <subject>Cognitive Psychology</subject>
                      <subj-group>
                        <subject>Perception</subject>
                        <subj-group>
                          <subject>Sensory Perception</subject>
                          <subj-group>
                            <subject>Vision</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Social Sciences</subject>
                  <subj-group>
                    <subject>Psychology</subject>
                    <subj-group>
                      <subject>Cognitive Psychology</subject>
                      <subj-group>
                        <subject>Perception</subject>
                        <subj-group>
                          <subject>Sensory Perception</subject>
                          <subj-group>
                            <subject>Vision</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Neuroscience</subject>
                    <subj-group>
                      <subject>Sensory Perception</subject>
                      <subj-group>
                        <subject>Vision</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Clinical Medicine</subject>
                    <subj-group>
                      <subject>Signs and Symptoms</subject>
                      <subj-group>
                        <subject>Lesions</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Physical Sciences</subject>
                  <subj-group>
                    <subject>Mathematics</subject>
                    <subj-group>
                      <subject>Applied Mathematics</subject>
                      <subj-group>
                        <subject>Algorithms</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Research and Analysis Methods</subject>
                  <subj-group>
                    <subject>Simulation and Modeling</subject>
                    <subj-group>
                      <subject>Algorithms</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Body Fluids</subject>
                      <subj-group>
                        <subject>Interstitial Fluid</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Body Fluids</subject>
                      <subj-group>
                        <subject>Interstitial Fluid</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Body Fluids</subject>
                      <subj-group>
                        <subject>Interstitial Fluid</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Biomarkers</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Utilization of deep learning to quantify fluid volume of neovascular age-related macular degeneration patients based on swept-source OCT imaging: The ONTARIO study</article-title>
                <alt-title alt-title-type="running-head">Utilizing deep learning to quantify fluid volume of nARMD patients based on SS-OCT imaging: The ONTARIO Study</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sodhi</surname>
                    <given-names>Simrat K.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pereira</surname>
                    <given-names>Austin</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2474-9609</contrib-id>
                  <name>
                    <surname>Oakley</surname>
                    <given-names>Jonathan D.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
                  <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
                  <xref rid="aff003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0363-7325</contrib-id>
                  <name>
                    <surname>Golding</surname>
                    <given-names>John</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <xref rid="aff004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Trimboli</surname>
                    <given-names>Carmelina</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
                  <xref rid="aff004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5713-1242</contrib-id>
                  <name>
                    <surname>Russakoff</surname>
                    <given-names>Daniel B.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
                  <xref rid="aff003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1998-2257</contrib-id>
                  <name>
                    <surname>Choudhry</surname>
                    <given-names>Netan</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="aff004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="aff005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="cor001" ref-type="corresp">*</xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Department of Ophthalmology &amp; Visual Sciences, University of Toronto, Toronto, ON Canada</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Voxeleron LLC, San Francisco, United States of America</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Vitreous Retina Macula Specialists of Toronto, Etobicoke, ON, Canada</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>Cleveland Clinic Canada, Toronto, ON, Canada</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Vavvas</surname>
                    <given-names>Demetrios G.</given-names>
                  </name>
                  <role>Editor</role>
                  <xref rid="edit1" ref-type="aff"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Massachusetts Eye &amp; Ear Infirmary, Harvard Medical School, UNITED STATES</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>The authors have read the journal’s policy and have the following competing interests: Authors JDO and DBR are employees of Voxeleron LLC. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>netan.choudhry@vrmto.com</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>14</day>
                <month>2</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2022</year>
              </pub-date>
              <volume>17</volume>
              <issue>2</issue>
              <elocation-id>e0262111</elocation-id>
              <history>
                <date date-type="received">
                  <day>28</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>17</day>
                  <month>12</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2022 Sodhi et al</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder>Sodhi et al</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0262111.pdf"/>
              <abstract>
                <sec id="sec001">
                  <title>Purpose</title>
                  <p>To evaluate the predictive ability of a deep learning-based algorithm to determine long-term best-corrected distance visual acuity (BCVA) outcomes in neovascular age-related macular degeneration (nARMD) patients using baseline swept-source optical coherence tomography (SS-OCT) and OCT-angiography (OCT-A) data.</p>
                </sec>
                <sec id="sec002">
                  <title>Methods</title>
                  <p>In this phase IV, retrospective, proof of concept, single center study, SS-OCT data from 17 previously treated nARMD eyes was used to assess retinal layer thicknesses, as well as quantify intraretinal fluid (IRF), subretinal fluid (SRF), and serous pigment epithelium detachments (PEDs) using a novel deep learning-based, macular fluid segmentation algorithm. Baseline OCT and OCT-A morphological features and fluid measurements were correlated using the Pearson correlation coefficient (PCC) to changes in BCVA from baseline to week 52.</p>
                </sec>
                <sec id="sec003">
                  <title>Results</title>
                  <p>Total retinal fluid (IRF, SRF and PED) volume at baseline had the strongest correlation to improvement in BCVA at month 12 (PCC = 0.652, p = 0.005). Fluid was subsequently sub-categorized into IRF, SRF and PED, with PED volume having the next highest correlation (PCC = 0.648, p = 0.005) to BCVA improvement. Average total retinal thickness in isolation demonstrated poor correlation (PCC = 0.334, p = 0.189). When two features, mean choroidal neovascular membranes (CNVM) size and total fluid volume, were combined and correlated with visual outcomes, the highest correlation increased to PCC = 0.695 (p = 0.002).</p>
                </sec>
                <sec id="sec004">
                  <title>Conclusions</title>
                  <p>In isolation, total fluid volume most closely correlates with change in BCVA values between baseline and week 52. In combination with complimentary information from OCT-A, an improvement in the linear correlation score was observed. Average total retinal thickness provided a lower correlation, and thus provides a lower predictive outcome than alternative metrics assessed. Clinically, a machine-learning approach to analyzing fluid metrics in combination with lesion size may provide an advantage in personalizing therapy and predicting BCVA outcomes at week 52.</p>
                </sec>
              </abstract>
              <funding-group>
                <award-group id="award001">
                  <funding-source>
                    <institution>National Center for Advancing Translational Sciences of the National Institutes</institution>
                  </funding-source>
                  <award-id>R44TR001890</award-id>
                </award-group>
                <award-group id="award002">
                  <funding-source>
                    <institution>Voxeleron LLC</institution>
                  </funding-source>
                </award-group>
                <award-group id="award003">
                  <funding-source>
                    <institution>Bayer Inc.</institution>
                  </funding-source>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1998-2257</contrib-id>
                    <name>
                      <surname>Choudhry</surname>
                      <given-names>Netan</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <funding-statement>Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number R44TR001890. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Voxeleron LLC. provided support in the form of a salary for authors JDO and DBR. This study was also supported by funding from Bayer Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="3"/>
                <table-count count="2"/>
                <page-count count="12"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>The dataset has been made publicly available via Dryad (<ext-link xlink:href="https://doi.org/10.5061/dryad.cc2fqz67f" ext-link-type="uri">https://doi.org/10.5061/dryad.cc2fqz67f</ext-link>).</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>The dataset has been made publicly available via Dryad (<ext-link xlink:href="https://doi.org/10.5061/dryad.cc2fqz67f" ext-link-type="uri">https://doi.org/10.5061/dryad.cc2fqz67f</ext-link>).</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec005">
              <title>Introduction</title>
              <p>Age-related macular degeneration (ARMD) remains the leading cause of blindness worldwide, with the prevalence expected to rise to 288 million by 2040 [<xref rid="pone.0262111.ref001" ref-type="bibr">1</xref>]. The mainstay of treatment for neovascular ARMD (nARMD) remains anti-vascular endothelial growth factor (VEGF) intravitreal injections due to the high efficacy and tolerable safety profile demonstrated in clinical trials [<xref rid="pone.0262111.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0262111.ref003" ref-type="bibr">3</xref>]. A recent meta-analysis found an overall increase of 7.37 letters in best corrected visual acuity (BCVA) at 1-year following intravitreal aflibercept treatment [<xref rid="pone.0262111.ref004" ref-type="bibr">4</xref>]. BCVA remains the most robust prognostic consideration in nARMD treatment trials [<xref rid="pone.0262111.ref005" ref-type="bibr">5</xref>]. Optical coherence tomography (OCT) imaging has allowed for anatomical assessment and correlation to treatment progression [<xref rid="pone.0262111.ref006" ref-type="bibr">6</xref>]. However, measurements used in initial pivotal clinical trials, such as central subfield thickness (CST), have recently demonstrated poor correlation to BCVA outcomes [<xref rid="pone.0262111.ref007" ref-type="bibr">7</xref>]. Fluid analysis of intraretinal cystoid fluid (IRF), subretinal fluid (SRF) and pigment-epithelial detachments (PED) have demonstrated promise in predicting functional deficits in nARMD, but currently lack consistent correlative results [<xref rid="pone.0262111.ref008" ref-type="bibr">8</xref>]. With patient demand increasing for accurate predictions in treatment outcomes, more diverse imaging biomarkers are crucial for providing accurate prognostic information.</p>
              <p>Optical coherence tomography angiography (OCT-A) has revealed further retinal anatomical and vascular structures to track nARMD progression [<xref rid="pone.0262111.ref009" ref-type="bibr">9</xref>]. Our 2021 proof of concept CANADA trial demonstrated significantly improved choroidal neovascularization membrane (CNVM) size identification for nARMD treatment monitoring through OCT-A [<xref rid="pone.0262111.ref010" ref-type="bibr">10</xref>]. However, fluid volume metrics and delineation of unique fluid characterization required extensive manual segmentation and demonstrated poor acquisition of real-time values [<xref rid="pone.0262111.ref010" ref-type="bibr">10</xref>]. It was hypothesized that artificial intelligence (AI) would improve image segmentation, ultimately providing better personalized therapy.</p>
              <p>Machine learning has bridged the gap in OCT imaging interpretation of biomarkers and nARMD disease monitoring. Rohm et al. in 2018 found that deep learning networks showed good visual predictions at 3-months following anti-VEGF treatment for nARMD [<xref rid="pone.0262111.ref011" ref-type="bibr">11</xref>]. Schlegl et al. in 2018 found deep learning networks in OCT imaging analysis led to excellent accuracy in retinal fluid type detection and segmentation for a variety of exudative disease processes [<xref rid="pone.0262111.ref012" ref-type="bibr">12</xref>]. Schmidt-Erfurth et al. in 2018 concluded that machine learning analysis of OCT images correlated with horizontal extension of IRF to final BCVA [<xref rid="pone.0262111.ref013" ref-type="bibr">13</xref>]. The Protocol T team also demonstrated automated segmentation of fluid on OCT imaging in diabetic macular edema patients through deep learning algorithms and concluded that SRF was associated with poor pre-treatment vision and positive anti-VEGF response [<xref rid="pone.0262111.ref014" ref-type="bibr">14</xref>].</p>
              <p>While AI models have postulated promise in OCT fluid segmentation and have demonstrated predictive value in anti-VEGF treatment outcomes, there are currently no trials demonstrating machine learning with swept-source OCT images in concordance with OCT-A analysis for nARMD patients. Therefore, our study was conducted as a follow-up, phase IV, proof-of-concept trial to evaluate a novel deep learning algorithm to determine BCVA outcomes in nARMD patients using both OCT and OCT-A imaging.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec006">
              <title>Methods</title>
              <sec id="sec007">
                <title>Study design</title>
                <p>Patients who previously completed the CANADA study were enrolled in this phase IV, retrospective, open-label proof-of-concept study. Analysis, as part of this study, began in July 2020 and ended in December 2020. The selection of participants for the CANADA study has been previously reported [<xref rid="pone.0262111.ref010" ref-type="bibr">10</xref>]. Twenty-three patients (25 eyes) completed the CANADA study and were enrolled into this study. No additional recruitment was performed as part of this study. This study was approved by the Institutional Review Board of Advarra and followed the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participants and was in accordance with current ICH/GCP guidelines, section 4.8.10.</p>
              </sec>
              <sec id="sec008">
                <title>Inclusion and exclusion criteria</title>
                <p>The key inclusion criteria were: (1) ≥ 25 years of age; (2) diagnosis of nARMD; (3) treatment naïve and (4) previously enrolled in the CANADA study. Exclusion criteria included patients with uncontrolled systemic hypertension or thromboembolic events (stroke, transient ischemic attack, myocardial infarction) within 6 months from baseline, ocular conditions affecting visual acuity besides nARMD (i.e. amblyopia, ischemic optic neuropathy, clinical significant diabetic macular edema, severe non-proliferative diabetic retinopathy, glaucoma, retinal detachment, retinal dystrophies, other retinal degenerations), ocular or periocular infection or active intraocular inflammation, hypersensitivity to aflibercept or any ingredient in the formulation, previous ocular surgery (including cataract extraction or YAG capsulotomy) within 3 months from baseline, planned ocular surgery throughout the study or previous treatments of laser photocoagulation or intravitreal anti-VEGF or steroid treatments. Pregnant women, nursing women, or patients unwilling to provide informed consent were also excluded.</p>
              </sec>
              <sec id="sec009">
                <title>Visits and treatment</title>
                <p>Participants were not treated as part of the ONTARIO study; however, participants were enrolled from the CANADA study where they were treated with initial 3 monthly injections (loading phase) of intravitreal aflibercept 2 mg at baseline, month 1 and month 2, then every other month for a total of 12 months (52 weeks).</p>
              </sec>
              <sec id="sec010">
                <title>Imaging</title>
                <p>As part of the CANADA study, all patients underwent SS-OCT-A testing using the Topcon Triton Swept Source OCT (Tokyo, Japan) to identify CST and lesion size at baseline [<xref rid="pone.0262111.ref010" ref-type="bibr">10</xref>]. The SS-OCT-A system has a scanning speed of 100,000 A-scans per second and utilizes a wavelength-sweeping laser, with a central wavelength of 1,050 nm wavelength and a sweeping range of approximately 100 nm [<xref rid="pone.0262111.ref015" ref-type="bibr">15</xref>]. The OCT-A B-scans were manually segmented into 6 slabs: vitreous, superficial, outer retina (OR), full macula, deep and choriocapillaris (CC). CNVM lesion size measurements were manually performed (SS and AP) and utilized the OR and CC slabs of 6 mm x 6mm OCT-A scans. OCT-A scans with a signal to noise ratio of &lt;7 were excluded from the study.</p>
                <p>Baseline 7 mm x 7 mm 3D macula volume scans containing 512 A-scans and 256 B-scans were segmented using a prototype version of the Orion software (Voxeleron LLC, San Francisco, USA). This performs layer segmentation as a pre-processing step to fluid segmentation that uses a deep learning-based algorithm. Performance of the fluid segmentation has previously been validated relative to two expert graders (SS and JO) [<xref rid="pone.0262111.ref010" ref-type="bibr">10</xref>].</p>
              </sec>
              <sec id="sec011">
                <title>Deep learning algorithm</title>
                <p>A deep learning-based algorithm was implemented to segment fluid regions within each OCT-volume. As reported previously, the method takes each OCT B-scan as input, and a segmentation mask is generated automatically using Orion software (San Francisco, CA, USA) [<xref rid="pone.0262111.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0262111.ref017" ref-type="bibr">17</xref>]. The deep learning architecture used for first the training, and subsequently the testing, was that of U-Net, which is a version of the autoencoder that uses skip connections to better maintain detail across different scales [<xref rid="pone.0262111.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0262111.ref019" ref-type="bibr">19</xref>]. U-Net uses three encoding/decoding levels, and learning was based on minimizing the model’s loss, where the loss function combines categorical cross entropy (CCE) and a weighted Dice similarity coefficient (DSC) (<xref rid="pone.0262111.g001" ref-type="fig">Fig 1</xref>).</p>
                <fig position="float" id="pone.0262111.g001">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0262111.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <p>Each (A) SS-OCT volume scan is first automatically segmented using Orion into 8 retinal interfaces. This results in (B) 7 layers that can be encoded into image form and used as an additional channel in model creation, thus encoding spatial information regarding the location of (C) fluid within the retina.</p>
                  </caption>
                  <graphic xlink:href="pone.0262111.g001" position="float"/>
                </fig>
              </sec>
              <sec id="sec012">
                <title>Statistical analysis</title>
                <p>All data are presented as either mean or mean ± SD. The BCVA was converted to the logarithm of the minimum angle of resolution (logMAR) for statistical purposes. Counting fingers vision was given a value of 1.85, and hand motions vision was given a value of 2.30 [<xref rid="pone.0262111.ref020" ref-type="bibr">20</xref>]. Statistical analysis was performed within Matlab (Natwick, MA, USA) and Excel (Microsoft, Redmond, WA, USA). Pearson’s Correlation Coefficient (PCC) was used to quantify the correlation between (i) BCVA and fluid volume and (ii) BCVA and CNVM lesion size. A P-value of &lt;0.05 was considered statistically significant. Pre-specified statistical analysis included: (1) correlation between BCVA and fluid volume at baseline and (2) correlation between BCVA and mean CNVM lesion size (mm<sup>2</sup>) at baseline.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec013">
              <title>Results</title>
              <sec id="sec014">
                <title>Patient characteristics</title>
                <sec id="sec015">
                  <title>Fluid segmentation training</title>
                  <p>Twenty-three patients (25 eyes) completed the CANADA study and were enrolled in this subsequent study. One patient was excluded based on image quality and subsequent layer segmentation issues. Therefore, the final cohort consisted of 22 patients (24 eyes). The average age of the patients was 76 years (range 48–89 years). Fifteen of the 22 treated patients were female and 7 of the 22 treated patients were male. Fifteen of the 24 eyes were pseudophakic and 2 of 24 eyes were phakic at baseline and were pseudophakic at week 52. For the entire cohort, the mean BCVA at baseline was 20/125 and improved to 20/80 by week 52 (p&lt;0.001).</p>
                  <p>Twenty-two SS-OCT volumes of the macula, comprising 5,632 images from the 22 nARMD subjects in the final cohort, were used to quantify IRF, SRF and fluid in serous PEDs. Assessment used 10-fold cross-validation, where each fold ensured no subject eye data was in both the training and testing data. In each fold, the training set used data augmentation such that one volume, comprising 256 B-scans, was replicated six times using random scaling, rotations and shifting. Given these were large input volumes and a heterogeneous input data set, the reported validation compared excellently to manual segmentations. Results showed strong correlation in all fluid volumes between the algorithm and the manually labeled data [<xref rid="pone.0262111.ref017" ref-type="bibr">17</xref>].</p>
                </sec>
                <sec id="sec016">
                  <title>Predictive analysis subgroup</title>
                  <p>OCT-A analysis was performed as part of the CANADA study to determine the mean CNVM lesion size (μm<sup>2</sup>). Of the final cohort of 22 patients (24 eyes) used in the fluid segmentation, 17 patients (18 eyes) had OCT-A data due to data or segmentation issues in 5 patients [<xref rid="pone.0262111.ref010" ref-type="bibr">10</xref>]. There were no serious adverse events throughout the course of the study. The mean age in this subgroup was consistent with the full cohort at 79 years (± 7.02). The mean BCVA at baseline was 20/125 and increased to 20/80 by week 52 (p = 0.0141).</p>
                </sec>
              </sec>
              <sec id="sec017">
                <title>Fluid analysis</title>
                <p>Total fluid volume at baseline and change in logMAR at month 12 relative to baseline had the closest correlation (PCC = 0.652, p = 0.005) (<xref rid="pone.0262111.t001" ref-type="table">Table 1</xref>). Fluid was subsequently sub-categorized into IRF, SRF and PED, with PED volume having the next highest correlation (PCC = 0.648, p = 0.005). Average total retinal thickness in isolation gave a lower correlation (PCC = 0.334, p = 0.189), and mean CNVM size (um<sup>2</sup>) from 3 mm OCT-A scans was very low (PCC = 0.072, p = 0.784). When two features were combined and correlated with visual outcomes, the best correlation increased to PCC = 0.695 (p = 0.002) using mean CNVM size and total fluid volume (<xref rid="pone.0262111.t002" ref-type="table">Table 2</xref>).</p>
                <table-wrap position="float" id="pone.0262111.t001">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0262111.t001</object-id>
                  <label>Table 1</label>
                  <caption>
                    <title>The top 10 correlating features to logMar change when ranked based on PCC.</title>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="pone.0262111.t001" id="pone.0262111.t001g" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">Feature 1 </th>
                          <th align="center" rowspan="1" colspan="1">Pearson’s Correlation Coefficient</th>
                          <th align="center" rowspan="1" colspan="1">p-value </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Total Fluid </td>
                          <td align="center" rowspan="1" colspan="1">0.6521 </td>
                          <td align="center" rowspan="1" colspan="1">0.0046 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">PED </td>
                          <td align="center" rowspan="1" colspan="1">0.6481 </td>
                          <td align="center" rowspan="1" colspan="1">0.0049 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">SRF </td>
                          <td align="center" rowspan="1" colspan="1">0.4824 </td>
                          <td align="center" rowspan="1" colspan="1">0.0499 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">6 mm average CST </td>
                          <td align="center" rowspan="1" colspan="1">0.3344 </td>
                          <td align="center" rowspan="1" colspan="1">0.1895 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Density map–central–% 6 mm </td>
                          <td align="center" rowspan="1" colspan="1">0.3241 </td>
                          <td align="center" rowspan="1" colspan="1">0.2045 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">6 mm inferior CST </td>
                          <td align="center" rowspan="1" colspan="1">0.3174 </td>
                          <td align="center" rowspan="1" colspan="1">0.2145 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">6 mm nasal </td>
                          <td align="center" rowspan="1" colspan="1">0.3122 </td>
                          <td align="center" rowspan="1" colspan="1">0.2225 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">6 mm temporal </td>
                          <td align="center" rowspan="1" colspan="1">0.2820 </td>
                          <td align="center" rowspan="1" colspan="1">0.2728 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Density map–superior–% 6 mm </td>
                          <td align="center" rowspan="1" colspan="1">0.2522 </td>
                          <td align="center" rowspan="1" colspan="1">0.3288 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">6 mm superior </td>
                          <td align="center" rowspan="1" colspan="1">0.2108 </td>
                          <td align="center" rowspan="1" colspan="1">0.4168 </td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                </table-wrap>
                <table-wrap position="float" id="pone.0262111.t002">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0262111.t002</object-id>
                  <label>Table 2</label>
                  <caption>
                    <title>The top 10 pairwise correlating features to logMar change when ranked based on PCC.</title>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="pone.0262111.t002" id="pone.0262111.t002g" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">Feature 1 </th>
                          <th align="center" rowspan="1" colspan="1">Feature 2 </th>
                          <th align="center" rowspan="1" colspan="1">Pearson’s Correlation Coefficient</th>
                          <th align="center" rowspan="1" colspan="1">p-value </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">CNVM Mean size (μm<sup>2</sup>)– 3 mm OCTA </td>
                          <td align="center" rowspan="1" colspan="1">Total Fluid </td>
                          <td align="center" rowspan="1" colspan="1">0.6951 </td>
                          <td align="center" rowspan="1" colspan="1">0.0099 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">PED </td>
                          <td align="center" rowspan="1" colspan="1">IRF </td>
                          <td align="center" rowspan="1" colspan="1">0.6752 </td>
                          <td align="center" rowspan="1" colspan="1">0.0141 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">CNVM Mean size (μm<sup>2</sup>)– 6 mm OCTA </td>
                          <td align="center" rowspan="1" colspan="1">Total Fluid </td>
                          <td align="center" rowspan="1" colspan="1">0.6751 </td>
                          <td align="center" rowspan="1" colspan="1">0.0141 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">CNVM Mean size (μm<sup>2</sup>)– 3 mm OCTA </td>
                          <td align="center" rowspan="1" colspan="1">PED </td>
                          <td align="center" rowspan="1" colspan="1">0.6721 </td>
                          <td align="center" rowspan="1" colspan="1">0.0149 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Total Fluid </td>
                          <td align="center" rowspan="1" colspan="1">SRF </td>
                          <td align="center" rowspan="1" colspan="1">0.6690 </td>
                          <td align="center" rowspan="1" colspan="1">0.0157 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Density map–inferior–% 6 mm </td>
                          <td align="center" rowspan="1" colspan="1">PED </td>
                          <td align="center" rowspan="1" colspan="1">0.6669 </td>
                          <td align="center" rowspan="1" colspan="1">0.0163 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Density map–superior–% 6 mm </td>
                          <td align="center" rowspan="1" colspan="1">Total Fluid </td>
                          <td align="center" rowspan="1" colspan="1">0.6659 </td>
                          <td align="center" rowspan="1" colspan="1">0.0165 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Total Fluid </td>
                          <td align="center" rowspan="1" colspan="1">IRF </td>
                          <td align="center" rowspan="1" colspan="1">0.6634 </td>
                          <td align="center" rowspan="1" colspan="1">0.0172 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Density map–inferior–% 6 mm </td>
                          <td align="center" rowspan="1" colspan="1">Total Fluid </td>
                          <td align="center" rowspan="1" colspan="1">0.6634 </td>
                          <td align="center" rowspan="1" colspan="1">0.0172 </td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">Density map–central–% 6 mm </td>
                          <td align="center" rowspan="1" colspan="1">PED </td>
                          <td align="center" rowspan="1" colspan="1">0.6606 </td>
                          <td align="center" rowspan="1" colspan="1">0.0181 </td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                </table-wrap>
                <p>Bland-Altman plots were used to assess the differences in agreement. In looking at the limits of agreement (LOA) in the Bland-Altman plots, we can evaluate the bias between the mean differences. <xref rid="pone.0262111.g002" ref-type="fig">Fig 2</xref> indicates narrow limits of agreement for both IRF and SRF. Fluid due to PED, however, shows wide LOA.</p>
                <fig position="float" id="pone.0262111.g002">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0262111.g002</object-id>
                  <label>Fig 2</label>
                  <caption>
                    <p>The manual versus automated reported total areas for each fluid type across all volumes on the left for IRF (A), SRF (C) and PED (E); and their corresponding Bland-Altman plots on the right for IRF (B), SRF (D) and PED (F). The correlation scores are 0.992, 0.986 and 0.820 for IRF, SRF and PED, respectively. For the Bland-Altman plots, the manual values are denoted with subscript ‘M’ and the automated values with ‘A’. Narrow limits of agreement are shown for IRF and SRF, but are larger for PED, as is addressed in the discussion.</p>
                  </caption>
                  <graphic xlink:href="pone.0262111.g002" position="float"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec018">
              <title>Discussion</title>
              <p>The use of AI to automate the analysis of ocular images and allow quantification of retinal biomarkers has increased in popularity globally. Previous studies in nARMD have used spectral domain OCT (SD-OCT) to quantify fluid and used this data to predict BCVA outcomes [<xref rid="pone.0262111.ref013" ref-type="bibr">13</xref>]. Our study is the first to use an automated approach to segment and quantify retinal fluid in SS-OCT scans, using a novel deep learning algorithm, and combine these findings with manual OCT-A segmentation to predict BCVA outcomes at month 12. This approach showed a close correlation between total fluid volume and change in BCVA values between baseline and week 52, which was strengthened when combined with complimentary information from OCT-A.</p>
              <p>Associating structural parameters derived from OCT data to functional outcomes has been a mainstay of clinical OCT since the ground-breaking PrONTO study [<xref rid="pone.0262111.ref021" ref-type="bibr">21</xref>]. Developments first in image processing techniques, and now based on deep learning, have advanced structural metrics far beyond overall retinal thickness as used in the PrONTO study. In taking advantage of such methods, we see different structure-function relationships that may be more relevant to disease type and treatment plans. In a clinical setting, it is not feasible to manually define such metrics, hence the relevance of automatic processing using AI-based methods, which allows precise outcomes without the need for manual, laborious delineation (<xref rid="pone.0262111.g001" ref-type="fig">Fig 1</xref>).</p>
              <p>Correlation in isolation provides no information about the differences in agreement and thus additional plots need to be employed [<xref rid="pone.0262111.ref022" ref-type="bibr">22</xref>]. In this study, we used Bland-Altman plots to assess the limits of agreement (LOA). A wide LOA, as seen with fluid due to PED, is interpreted to be related to the challenge in delineating PEDs containing mostly fluid and those containing tissue. It is challenging for the grader to be consistent in their labelling, which results in larger discrepancies in the data, as evidenced in this plot.</p>
              <p>The use of swept-source scans has the potential to increase the precision and recall of our automated algorithm as swept-source devices use a narrower wavelength of light and captures 100,000 A-scans per second, rather than ~68,000 A-scans that are captured by SD-OCT devices [<xref rid="pone.0262111.ref023" ref-type="bibr">23</xref>]. The increase in scans frequency allows for quicker image acquisition and denser scan patterns at wider fields of view than standard SD-OCT [<xref rid="pone.0262111.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0262111.ref025" ref-type="bibr">25</xref>]. This is clinically significant as it can reduce motion in the data as well as patient imaging time, improving both the quality of the data as well as the patient experience. SS-OCT and SS-OCT-A data provides extensive volumetric information and the use of AI-coupled SS-OCT-A, has the potential to become the first-line diagnostic tool in nARMD [<xref rid="pone.0262111.ref026" ref-type="bibr">26</xref>]. A further advantage of the SS-OCT devices is that the longer wavelength of the light source allows for deeper penetration of the choroid, resolving choroidal structures relevant to several sight-threatening diseases. Deep learning algorithms, that harness SS-OCT’s ability to penetrate the choroid, have already been developed and can segment the choroidal-scleral boundary to quantify choroidal volume [<xref rid="pone.0262111.ref027" ref-type="bibr">27</xref>, <xref rid="pone.0262111.ref028" ref-type="bibr">28</xref>].</p>
              <p>Due to its historical use in clinical trials, CST is currently used extensively for assessing treatment response and determining the next treatment date [<xref rid="pone.0262111.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0262111.ref029" ref-type="bibr">29</xref>]. The discrepancy between functional outcomes, measured using BCVA, and anatomical outcomes, measured using CST, is well known in the field [<xref rid="pone.0262111.ref007" ref-type="bibr">7</xref>]. <xref rid="pone.0262111.t001" ref-type="table">Table 1</xref> demonstrates a similar trend as the average total retinal thickness in isolation gave a lower correlation. Fluid volume is a more robust marker, as was shown in previous reports, as well as in our analysis [<xref rid="pone.0262111.ref008" ref-type="bibr">8</xref>]. When the fluid was sub-categorized into IRF, SRF and PED, the correlation was highest for PED, followed by SRF and IRF. When two parameters were combined, total fluid and CNVM mean lesion size provided the strongest correlation (PCC = 0.695, p = 0.002) to BCVA at month 12 (<xref rid="pone.0262111.t002" ref-type="table">Table 2</xref>).</p>
              <p>Qualitative features of OCT-A scans, including medusa form, sea-fan form, pruned vascular tree pattern, tangled network pattern and vascular loop, can be assessed without the need for adjuvant software [<xref rid="pone.0262111.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0262111.ref031" ref-type="bibr">31</xref>]. A larger sample size would assist in identifying the association of various CNVM patterns on OCT-A and their prognostic value using an AI-based approach. Quantitative measures, including total vascular area (TVA), the total area (TA) and the vascular density (VD), require add-on algorithms or time-consuming manual measurements [<xref rid="pone.0262111.ref032" ref-type="bibr">32</xref>, <xref rid="pone.0262111.ref033" ref-type="bibr">33</xref>]. Manual measurements, such as those employed by Jia et al., involved quantification of blood flow within a CNV by multiplying the number of pixels and the pixel size after using the split-spectrum amplitude-decorrelation angiography (SSADA) algorithm to improve the signal-to-noise ratio [<xref rid="pone.0262111.ref033" ref-type="bibr">33</xref>]. Whereas Taibouni et al developed an automated segmentation algorithm that reduced noise and enhanced vessels by Frangi filtering [<xref rid="pone.0262111.ref032" ref-type="bibr">32</xref>]. Currently, an embedded, quantitative algorithm does not exist in OCT-A devices, which makes it difficult to perform these measurements in a routine clinical practice. However, based on the results of this study, it is imperative to perform these measurements as they increase the predictive outcome when correlated with OCT features (<xref rid="pone.0262111.g003" ref-type="fig">Fig 3</xref>). The addition of mean lesion size, using OCT-A, may have increased the correlation with BCVA at month 12 because OCT-A provides information on the activation of the lesion [<xref rid="pone.0262111.ref034" ref-type="bibr">34</xref>]. In future studies, a larger number of OCT-A parameters should be analyzed to provide a wholistic ranking of features that increase predictability of long-term visual outcomes.</p>
              <fig position="float" id="pone.0262111.g003">
                <object-id pub-id-type="doi">10.1371/journal.pone.0262111.g003</object-id>
                <label>Fig 3</label>
                <caption>
                  <p>(A) SS-OCT volume scan of 87-year-old female patient with type I CNV, SRF and epiretinal membrane (ERM); (B) fluid segmentation using a convolutional neural network (CNN) highlights SRF in blue; (C) corresponding OCT-A scan depicting segmented CNVM from outer retina (OR) slab; (D) density flow highlighting areas of increased flow; (E) corresponding flow B-scan from single horizontal B-scan through center of CNVM.</p>
                </caption>
                <graphic xlink:href="pone.0262111.g003" position="float"/>
              </fig>
              <p>Several OCT and OCT-A biomarkers have been linked to visual outcomes in nARMD, including, but not limited to, branching patterns, total number of branch points, junction density, hyperreflective foci [<xref rid="pone.0262111.ref035" ref-type="bibr">35</xref>–<xref rid="pone.0262111.ref038" ref-type="bibr">38</xref>]. In this study, we have analyzed a sub-set of these biomarkers, but others should be studied to expand the list of features that are predictive of long-term visual outcomes. In our study, PED volume and IRF were predictive of visual function, however the presence or persistence of a PED may still allow a patient to achieve a relatively fair visual acuity [<xref rid="pone.0262111.ref039" ref-type="bibr">39</xref>]. The predictive outcomes of specific fluid types (i.e. IRF, SRF or PED) may also vary depending on the patients included in the study. A limitation of this study was the number of patients included. To have a more robust fluid analysis, not only does the total number of patients need to be higher, but each of the fluid subtypes being evaluated needs to have a similar number of scans analyzed. Increasing the number of timepoints can also provide further information as to which biomarkers are predictive early or later in treatment. Eventually a potential “retinal calculator” could be created that allows multiple parameters can be considered at one time.</p>
              <p>This study demonstrates the clinical implementation of a novel, deep learning-based algorithm and the importance of including OCT-A quantitative parameters to existing fluid analysis algorithms to increase the predictive power. Delineating lesion size on OCT-A scans either requires time-intensive manual segmentation or additional automated software, however the inclusion of OCT-A-related parameters may be key to accurately predicting long-term visual outcomes.</p>
            </sec>
          </body>
          <back>
            <ref-list>
              <title>References</title>
              <ref id="pone.0262111.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>WL</given-names></name>, <name><surname>Su</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Cheung</surname><given-names>CMG</given-names></name>, <name><surname>Klein</surname><given-names>R</given-names></name>, <name><surname>Cheng</surname><given-names>C-Y</given-names></name>, <etal>et al</etal>. <article-title>Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis</article-title>. <source>Lancet Global Heal</source>. <year>2014</year>;<volume>2</volume>(<issue>2</issue>):<fpage>e106</fpage>–<lpage>16</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S2214-109X(13)70145-1</pub-id>
<?supplied-pmid 25104651?><pub-id pub-id-type="pmid">25104651</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Rosenfeld</surname><given-names>PJ</given-names></name>, <name><surname>Brown</surname><given-names>DM</given-names></name>, <name><surname>Heier</surname><given-names>JS</given-names></name>, <name><surname>Boyer</surname><given-names>DS</given-names></name>, <name><surname>Kaiser</surname><given-names>PK</given-names></name>, <name><surname>Chung</surname><given-names>CY</given-names></name>, <etal>et al</etal>. <article-title>Ranibizumab for Neovascular Age-Related Macular Degeneration</article-title>. <source>New Engl J Medicine</source>. <year>2006</year>;<volume>355</volume>(<issue>14</issue>):<fpage>1419</fpage>–<lpage>31</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0262111.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Busbee</surname><given-names>BG</given-names></name>, <name><surname>Ho</surname><given-names>AC</given-names></name>, <name><surname>Brown</surname><given-names>DM</given-names></name>, <name><surname>Heier</surname><given-names>JS</given-names></name>, <name><surname>Suñer</surname><given-names>IJ</given-names></name>, <name><surname>Li</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration</article-title>. <source>Ophthalmology</source>. <year>2013</year>;<volume>120</volume>(<issue>5</issue>):<fpage>1046</fpage>–<lpage>56</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ophtha.2012.10.014</pub-id>
<?supplied-pmid 23352196?><pub-id pub-id-type="pmid">23352196</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>MY</given-names></name>, <name><surname>Cheng</surname><given-names>J</given-names></name>, <name><surname>Etminan</surname><given-names>M</given-names></name>, <name><surname>Zafari</surname><given-names>Z</given-names></name>, <name><surname>Maberley</surname><given-names>D</given-names></name>. <article-title>One year effectiveness study of intravitreal aflibercept in neovascular age‐related macular degeneration: a meta‐analysis</article-title>. <source>Acta Ophthalmol.</source><year>2019</year>;<volume>97</volume>(<issue>1</issue>):<fpage>e1</fpage>–<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/aos.13825</pub-id>
<?supplied-pmid 30030923?><pub-id pub-id-type="pmid">30030923</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Schmidt-Erfurth</surname><given-names>U</given-names></name>, <name><surname>Waldstein</surname><given-names>SM</given-names></name>. <article-title>A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration</article-title>. <source>Prog Retin Eye Res</source>. <year>2016</year>;<volume>50</volume>:<fpage>1</fpage>–<lpage>24</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.preteyeres.2015.07.007</pub-id>
<?supplied-pmid 26307399?><pub-id pub-id-type="pmid">26307399</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Wilde</surname><given-names>C</given-names></name>, <name><surname>Patel</surname><given-names>M</given-names></name>, <name><surname>Lakshmanan</surname><given-names>A</given-names></name>, <name><surname>Amankwah</surname><given-names>R</given-names></name>, <name><surname>Dhar-Munshi</surname><given-names>S</given-names></name>, <name><surname>Amoaku</surname><given-names>W</given-names></name>, <etal>et al</etal>. <article-title>The diagnostic accuracy of spectral-domain optical coherence tomography for neovascular age-related macular degeneration: a comparison with fundus fluorescein angiography</article-title>. <source>Eye</source>. <year>2015</year>;<volume>29</volume>(<issue>5</issue>):<fpage>602</fpage>–<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/eye.2015.44</pub-id>
<?supplied-pmid 25907206?><pub-id pub-id-type="pmid">25907206</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Bressler</surname><given-names>NM</given-names></name>, <name><surname>Odia</surname><given-names>I</given-names></name>, <name><surname>Maguire</surname><given-names>M</given-names></name>, <name><surname>Glassman</surname><given-names>AR</given-names></name>, <name><surname>Jampol</surname><given-names>LM</given-names></name>, <name><surname>MacCumber</surname><given-names>MW</given-names></name>, <etal>et al</etal>. <article-title>Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab</article-title>. <source>Jama Ophthalmol</source>. <year>2019</year>;<volume>137</volume>(<issue>9</issue>):<fpage>977</fpage>–<lpage>85</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2019.1963</pub-id>
<?supplied-pmid 31246237?><pub-id pub-id-type="pmid">31246237</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Klimscha</surname><given-names>S</given-names></name>, <name><surname>Waldstein</surname><given-names>SM</given-names></name>, <name><surname>Schlegl</surname><given-names>T</given-names></name>, <name><surname>Bogunović</surname><given-names>H</given-names></name>, <name><surname>Sadeghipour</surname><given-names>A</given-names></name>, <name><surname>Philip</surname><given-names>A-M</given-names></name>, <etal>et al</etal>. <article-title>Spatial Correspondence Between Intraretinal Fluid, Subretinal Fluid, and Pigment Epithelial Detachment in Neovascular Age-Related Macular Degeneration Spatial Correspondence of Fluid in Neovascular AMD</article-title>. <source>Invest Ophth Vis Sci</source>. <year>2017</year>;<volume>58</volume>(<issue>10</issue>):<fpage>4039</fpage>–<lpage>48</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0262111.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Perrott-Reynolds</surname><given-names>R</given-names></name>, <name><surname>Cann</surname><given-names>R</given-names></name>, <name><surname>Cronbach</surname><given-names>N</given-names></name>, <name><surname>Neo</surname><given-names>YN</given-names></name>, <name><surname>Ho</surname><given-names>V</given-names></name>, <name><surname>McNally</surname><given-names>O</given-names></name>, <etal>et al</etal>. <article-title>The diagnostic accuracy of OCT angiography in naive and treated neovascular age-related macular degeneration: a review</article-title>. <source>Eye</source>. <year>2019</year>;<volume>33</volume>(<issue>2</issue>):<fpage>274</fpage>–<lpage>82</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41433-018-0229-6</pub-id>
<?supplied-pmid 30382236?><pub-id pub-id-type="pmid">30382236</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Sodhi</surname><given-names>SK</given-names></name>, <name><surname>Trimboli</surname><given-names>C</given-names></name>, <name><surname>Kalaichandran</surname><given-names>S</given-names></name>, <name><surname>Pereira</surname><given-names>A</given-names></name>, <name><surname>Choudhry</surname><given-names>N</given-names></name>. <article-title>A proof of concept study to evaluate the treatment response of aflibercept in wARMD using OCT-A (Canada study)</article-title>. <source>Int Ophthalmol</source>. <year>2021</year>;<fpage>1</fpage>–<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10792-020-01545-8</pub-id>
<?supplied-pmid 32813193?><pub-id pub-id-type="pmid">32813193</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Rohm</surname><given-names>M</given-names></name>, <name><surname>Tresp</surname><given-names>V</given-names></name>, <name><surname>Müller</surname><given-names>M</given-names></name>, <name><surname>Kern</surname><given-names>C</given-names></name>, <name><surname>Manakov</surname><given-names>I</given-names></name>, <name><surname>Weiss</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Predicting Visual Acuity by Using Machine Learning in Patients Treated for Neovascular Age-Related Macular Degeneration</article-title>. <source>Ophthalmology</source>. <year>2018</year>;<volume>125</volume>(<issue>7</issue>):<fpage>1028</fpage>–<lpage>36</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ophtha.2017.12.034</pub-id>
<?supplied-pmid 29454659?><pub-id pub-id-type="pmid">29454659</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Schlegl</surname><given-names>T</given-names></name>, <name><surname>Waldstein</surname><given-names>SM</given-names></name>, <name><surname>Bogunovic</surname><given-names>H</given-names></name>, <name><surname>Endstraßer</surname><given-names>F</given-names></name>, <name><surname>Sadeghipour</surname><given-names>A</given-names></name>, <name><surname>Philip</surname><given-names>A-M</given-names></name>, <etal>et al</etal>. <article-title>Fully Automated Detection and Quantification of Macular Fluid in OCT Using Deep Learning</article-title>. <source>Ophthalmology</source>. <year>2018</year>;<volume>125</volume>(<issue>4</issue>):<fpage>549</fpage>–<lpage>58</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ophtha.2017.10.031</pub-id>
<?supplied-pmid 29224926?><pub-id pub-id-type="pmid">29224926</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Schmidt-Erfurth</surname><given-names>U</given-names></name>, <name><surname>Bogunovic</surname><given-names>H</given-names></name>, <name><surname>Sadeghipour</surname><given-names>A</given-names></name>, <name><surname>Schlegl</surname><given-names>T</given-names></name>, <name><surname>Langs</surname><given-names>G</given-names></name>, <name><surname>Gerendas</surname><given-names>BS</given-names></name>, <etal>et al</etal>. <article-title>Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration</article-title>. <source>Ophthalmol Retin</source>. <year>2018</year>;<volume>2</volume>(<issue>1</issue>):<fpage>24</fpage>–<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.oret.2017.03.015</pub-id>
<?supplied-pmid 31047298?><pub-id pub-id-type="pmid">31047298</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>PK</given-names></name>, <name><surname>Vogl</surname><given-names>W-D</given-names></name>, <name><surname>Gerendas</surname><given-names>BS</given-names></name>, <name><surname>Glassman</surname><given-names>AR</given-names></name>, <name><surname>Bogunovic</surname><given-names>H</given-names></name>, <name><surname>Jampol</surname><given-names>LM</given-names></name>, <etal>et al</etal>. <article-title>Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning</article-title>. <source>Jama Ophthalmol</source>. <year>2020</year>;<volume>138</volume>(<issue>9</issue>):<fpage>945</fpage>–<lpage>53</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2020.2457</pub-id>
<?supplied-pmid 32722799?><pub-id pub-id-type="pmid">32722799</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>Q</given-names></name>, <name><surname>Thorell</surname><given-names>MR</given-names></name>, <name><surname>An</surname><given-names>L</given-names></name>, <name><surname>Durbin</surname><given-names>MK</given-names></name>, <name><surname>Laron</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Swept-Source OCT Angiography of the Retinal Vasculature Using Intensity Differentiation-based Optical Microangiography Algorithms</article-title>. <source>Ophthalmic Surg Lasers Imaging Retin</source>. <year>2014</year>;<volume>45</volume>(<issue>5</issue>):<fpage>382</fpage>–<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3928/23258160-20140909-08</pub-id>
<?supplied-pmid 25230403?><pub-id pub-id-type="pmid">25230403</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Oakley</surname><given-names>JD</given-names></name>, <name><surname>Gabilondo</surname><given-names>I</given-names></name>, <name><surname>Songster</surname><given-names>C</given-names></name>, <name><surname>Russakoff</surname><given-names>D</given-names></name>, <name><surname>Green</surname><given-names>A</given-names></name>, <name><surname>Villoslada</surname><given-names>P</given-names></name>. <article-title>Assessing Manual versus Automated Segmentation of the Macula using Optical Coherence Tomography | IOVS | ARVO Journals.</article-title><source>Investigative Ophthalmology &amp; Visual Science</source>. <year>2014</year>;<volume>55</volume>:<fpage>4790</fpage>.<pub-id pub-id-type="pmid">25091414</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Oakley</surname><given-names>JD</given-names></name>, <name><surname>Sodhi</surname><given-names>SK</given-names></name>, <name><surname>Russakoff</surname><given-names>DB</given-names></name>, <name><surname>Choudhry</surname><given-names>N</given-names></name>. <article-title>Automated Deep Learning-based Multi-class Fluid Segmentation in Swept-Source Optical Coherence Tomography Images</article-title>. <source>Biorxiv</source>. <year>2020</year>;2020.09.01.278259.</mixed-citation>
              </ref>
              <ref id="pone.0262111.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Badrinarayanan</surname><given-names>V</given-names></name>, <name><surname>Kendall</surname><given-names>A</given-names></name>, <name><surname>Cipolla</surname><given-names>R</given-names></name>. <article-title>SegNet: A Deep Convolutional Encoder-Decoder Architecture for Image Segmentation.</article-title><source>Ieee T Pattern Anal</source>. <year>2015</year>;<volume>39</volume>(<issue>12</issue>):<fpage>2481</fpage>–<lpage>95</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0262111.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Ronneberger</surname><given-names>O</given-names></name>, <name><surname>Fischer</surname><given-names>P</given-names></name>, <name><surname>Brox</surname><given-names>T</given-names></name>. <article-title>U-Net: Convolutional Networks for Biomedical Image Segmentation</article-title>. <source>Arxiv</source>. <year>2015</year>.</mixed-citation>
              </ref>
              <ref id="pone.0262111.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Schulze-Bonsel</surname><given-names>K</given-names></name>, <name><surname>Feltgen</surname><given-names>N</given-names></name>, <name><surname>Burau</surname><given-names>H</given-names></name>, <name><surname>Hansen</surname><given-names>L</given-names></name>, <name><surname>Bach</surname><given-names>M</given-names></name>. <article-title>Visual Acuities “Hand Motion” and “Counting Fingers” Can Be Quantified with the Freiburg Visual Acuity Test</article-title>. <source>Invest Ophth Vis Sci.</source><year>2006</year>;<volume>47</volume>(<issue>3</issue>):<fpage>1236</fpage>–<lpage>40</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1167/iovs.05-0981</pub-id>
<?supplied-pmid 16505064?><pub-id pub-id-type="pmid">16505064</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Lalwani</surname><given-names>GA</given-names></name>, <name><surname>Rosenfeld</surname><given-names>PJ</given-names></name>, <name><surname>Fung</surname><given-names>AE</given-names></name>, <name><surname>Dubovy</surname><given-names>SR</given-names></name>, <name><surname>Michels</surname><given-names>S</given-names></name>, <name><surname>Feuer</surname><given-names>W</given-names></name>, <etal>et al</etal>. <article-title>A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study</article-title>. <source>Am J Ophthalmol</source>. <year>2009</year>;<volume>148</volume>(<issue>1</issue>):<fpage>43</fpage>–<lpage>58.e1</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajo.2009.01.024</pub-id>
<?supplied-pmid 19376495?><pub-id pub-id-type="pmid">19376495</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Giavarina</surname><given-names>D.</given-names></name><article-title>Understanding Bland Altman analysis</article-title>. <source>Biochem Medica</source>. <year>2015</year>;<volume>25</volume>(<issue>2</issue>):<fpage>141</fpage>–<lpage>51</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.11613/BM.2015.015</pub-id>
<?supplied-pmid 26110027?><pub-id pub-id-type="pmid">26110027</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Miller</surname><given-names>AR</given-names></name>, <name><surname>Roisman</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>Q</given-names></name>, <name><surname>Zheng</surname><given-names>F</given-names></name>, <name><surname>Dias</surname><given-names>JR de O</given-names></name>, <name><surname>Yehoshua</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Comparison Between Spectral-Domain and Swept-Source Optical Coherence Tomography Angiographic Imaging of Choroidal Neovascularization Imaging of CNV With SS-OCTA and SD-OCTA</article-title>. <source>Invest Ophth Vis Sci.</source><year>2017</year>;<volume>58</volume>(<issue>3</issue>):<fpage>1499</fpage>–<lpage>505</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0262111.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Kishi</surname><given-names>S.</given-names></name><article-title>Impact of swept source optical coherence tomography on ophthalmology</article-title>. <source>Taiwan J Ophthalmol</source>. <year>2016</year>;<volume>6</volume>(<issue>2</issue>):<fpage>58</fpage>–<lpage>68</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.tjo.2015.09.002</pub-id>
<?supplied-pmid 29018713?><pub-id pub-id-type="pmid">29018713</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Spaide</surname><given-names>RF</given-names></name>, <name><surname>Klancnik</surname><given-names>JM</given-names></name>, <name><surname>Cooney</surname><given-names>MJ</given-names></name>. <article-title>Retinal Vascular Layers Imaged by Fluorescein Angiography and Optical Coherence Tomography Angiography</article-title>. <source>Jama Ophthalmol</source>. <year>2015</year>;<volume>133</volume>(<issue>1</issue>):<fpage>45</fpage>–<lpage>50</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2014.3616</pub-id>
<?supplied-pmid 25317632?><pub-id pub-id-type="pmid">25317632</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Laíns</surname><given-names>I</given-names></name>, <name><surname>Wang</surname><given-names>JC</given-names></name>, <name><surname>Cui</surname><given-names>Y</given-names></name>, <name><surname>Katz</surname><given-names>R</given-names></name>, <name><surname>Vingopoulos</surname><given-names>F</given-names></name>, <name><surname>Staurenghi</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Retinal applications of swept source optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA).</article-title><source>Prog Retin Eye Res</source>. <year>2021</year>;<volume>84</volume>:<fpage>100951</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.preteyeres.2021.100951</pub-id><?supplied-pmid 33516833?><pub-id pub-id-type="pmid">33516833</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Tsuji</surname><given-names>S</given-names></name>, <name><surname>Sekiryu</surname><given-names>T</given-names></name>, <name><surname>Sugano</surname><given-names>Y</given-names></name>, <name><surname>Ojima</surname><given-names>A</given-names></name>, <name><surname>Kasai</surname><given-names>A</given-names></name>, <name><surname>Okamoto</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Semantic Segmentation of the Choroid in Swept Source Optical Coherence Tomography Images for Volumetrics</article-title>. <source>Sci Rep-uk</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>1088</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-020-57788-z</pub-id><?supplied-pmid 31974487?><pub-id pub-id-type="pmid">31974487</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>Bi</surname><given-names>L</given-names></name>, <name><surname>Xu</surname><given-names>Y</given-names></name>, <name><surname>Feng</surname><given-names>D</given-names></name>, <name><surname>Kim</surname><given-names>J</given-names></name>, <name><surname>Xu</surname><given-names>X</given-names></name>. <article-title>Robust deep learning method for choroidal vessel segmentation on swept source optical coherence tomography images</article-title>. <source>Biomed Opt Express</source>. <year>2019</year>;<volume>10</volume>(<issue>4</issue>):<fpage>1601</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1364/BOE.10.001601</pub-id><?supplied-pmid 31061759?><pub-id pub-id-type="pmid">31061759</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Heier</surname><given-names>JS</given-names></name>, <name><surname>Brown</surname><given-names>DM</given-names></name>, <name><surname>Chong</surname><given-names>V</given-names></name>, <name><surname>Korobelnik</surname><given-names>J-F</given-names></name>, <name><surname>Kaiser</surname><given-names>PK</given-names></name>, <name><surname>Nguyen</surname><given-names>QD</given-names></name>, <etal>et al</etal>. <article-title>Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration</article-title>. <source>Ophthalmology</source>. <year>2012</year>;<volume>119</volume>(<issue>12</issue>):<fpage>2537</fpage>–<lpage>48</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ophtha.2012.09.006</pub-id>
<?supplied-pmid 23084240?><pub-id pub-id-type="pmid">23084240</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Miere</surname><given-names>A</given-names></name>, <name><surname>Querques</surname><given-names>G</given-names></name>, <name><surname>Semoun</surname><given-names>O</given-names></name>, <name><surname>Amoroso</surname><given-names>F</given-names></name>, <name><surname>Zambrowski</surname><given-names>O</given-names></name>, <name><surname>Chapron</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Optical coherence tomography angiography changes in early type 3 neovascularization after anti-vascular endothelial growth factor treatment</article-title>. <source>Retin</source>. <year>2017</year>;<volume>37</volume>(<issue>10</issue>):<fpage>1873</fpage>–<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/IAE.0000000000001447</pub-id>
<?supplied-pmid 28079756?><pub-id pub-id-type="pmid">28079756</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref031">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>Kuehlewein</surname><given-names>L</given-names></name>, <name><surname>Bansal</surname><given-names>M</given-names></name>, <name><surname>Lenis</surname><given-names>TL</given-names></name>, <name><surname>Iafe</surname><given-names>NA</given-names></name>, <name><surname>Sadda</surname><given-names>SR</given-names></name>, <name><surname>Filho</surname><given-names>MAB</given-names></name>, <etal>et al</etal>. <article-title>Optical Coherence Tomography Angiography of Type 1 Neovascularization in Age-Related Macular Degeneration</article-title>. <source>Am J Ophthalmol</source>. <year>2015</year>;<volume>160</volume>(<issue>4</issue>):<fpage>739</fpage>–<lpage>748.e2</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajo.2015.06.030</pub-id>
<?supplied-pmid 26164826?><pub-id pub-id-type="pmid">26164826</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref032">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>Taibouni</surname><given-names>K</given-names></name>, <name><surname>Chenoune</surname><given-names>Y</given-names></name>, <name><surname>Miere</surname><given-names>A</given-names></name>, <name><surname>Colantuono</surname><given-names>D</given-names></name>, <name><surname>Souied</surname><given-names>E</given-names></name>, <name><surname>Petit</surname><given-names>E</given-names></name>. <article-title>Automated quantification of choroidal neovascularization on Optical Coherence Tomography Angiography images</article-title>. <source>Comput Biol Med</source>. <year>2019</year>;<volume>114</volume>:<fpage>103450</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.compbiomed.2019.103450</pub-id><?supplied-pmid 31550556?><pub-id pub-id-type="pmid">31550556</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Jia</surname><given-names>Y</given-names></name>, <name><surname>Bailey</surname><given-names>ST</given-names></name>, <name><surname>Wilson</surname><given-names>DJ</given-names></name>, <name><surname>Tan</surname><given-names>O</given-names></name>, <name><surname>Klein</surname><given-names>ML</given-names></name>, <name><surname>Flaxel</surname><given-names>CJ</given-names></name>, <etal>et al</etal>. <article-title>Quantitative Optical Coherence Tomography Angiography of Choroidal Neovascularization in Age-Related Macular Degeneration</article-title>. <source>Ophthalmology</source>. <year>2014</year>;<volume>121</volume>(<issue>7</issue>):<fpage>1435</fpage>–<lpage>44</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ophtha.2014.01.034</pub-id>
<?supplied-pmid 24679442?><pub-id pub-id-type="pmid">24679442</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>D</given-names></name>, <name><surname>Jia</surname><given-names>Y</given-names></name>, <name><surname>Rispoli</surname><given-names>M</given-names></name>, <name><surname>Tan</surname><given-names>O</given-names></name>, <name><surname>Lumbroso</surname><given-names>B</given-names></name>. <article-title>Optical Coherence Tomography Angiography of Time Course of Choroidal Neovascularization in Response to Anti-Angiogenic Treatment.</article-title><source>Retin</source>. <year>2015</year>;<volume>35</volume>(<issue>11</issue>):<fpage>2260</fpage>–<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/IAE.0000000000000846</pub-id>
<?supplied-pmid 26469535?><pub-id pub-id-type="pmid">26469535</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Al-Sheikh</surname><given-names>M</given-names></name>, <name><surname>Iafe</surname><given-names>NA</given-names></name>, <name><surname>Phasukkijwatana</surname><given-names>N</given-names></name>, <name><surname>Sadda</surname><given-names>SR</given-names></name>, <name><surname>Sarraf</surname><given-names>D</given-names></name>. <article-title>Biomarkers of Neovascular Activity in Age-Related Macular Degeneration Using Optical Coherence Tomography Angiography</article-title>. <source>Retin</source>. <year>2018</year>;<volume>38</volume>(<issue>2</issue>):<fpage>220</fpage>–<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/IAE.0000000000001628</pub-id>
<?supplied-pmid 28582276?><pub-id pub-id-type="pmid">28582276</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Told</surname><given-names>R</given-names></name>, <name><surname>Reiter</surname><given-names>G</given-names></name>, <name><surname>Schranz</surname><given-names>M</given-names></name>, <name><surname>Reumueller</surname><given-names>A</given-names></name>, <name><surname>Hacker</surname><given-names>V</given-names></name>, <name><surname>Mittermueller</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Correlation of retinal thickness and swept-source optical coherence tomography angiography derived vascular changes in patients with neovascular age-related macular degeneration</article-title>. <source>Curr Eye Res</source>. <year>2020</year>.</mixed-citation>
              </ref>
              <ref id="pone.0262111.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>Casalino</surname><given-names>G</given-names></name>, <name><surname>Stevenson</surname><given-names>MR</given-names></name>, <name><surname>Bandello</surname><given-names>F</given-names></name>, <name><surname>Chakravarthy</surname><given-names>U</given-names></name>. <article-title>Tomographic Biomarkers Predicting Progression to Fibrosis in Treated Neovascular Age-Related Macular Degeneration: A Multimodal Imaging Study</article-title>. <source>Ophthalmol Retin</source>. <year>2018</year>;<volume>2</volume>(<issue>5</issue>):<fpage>451</fpage>–<lpage>61</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.oret.2017.08.019</pub-id>
<?supplied-pmid 31047325?><pub-id pub-id-type="pmid">31047325</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref038">
                <label>38</label>
                <mixed-citation publication-type="journal"><name><surname>Waldstein</surname><given-names>SM</given-names></name>, <name><surname>Vogl</surname><given-names>W-D</given-names></name>, <name><surname>Bogunovic</surname><given-names>H</given-names></name>, <name><surname>Sadeghipour</surname><given-names>A</given-names></name>, <name><surname>Riedl</surname><given-names>S</given-names></name>, <name><surname>Schmidt-Erfurth</surname><given-names>U</given-names></name>. <article-title>Characterization of Drusen and Hyperreflective Foci as Biomarkers for Disease Progression in Age-Related Macular Degeneration Using Artificial Intelligence in Optical Coherence Tomography.</article-title><source>Jama Ophthalmol</source>. <year>2020</year>;<volume>138</volume>(<issue>7</issue>):<fpage>740</fpage>–<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2020.1376</pub-id>
<?supplied-pmid 32379287?><pub-id pub-id-type="pmid">32379287</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262111.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Cheong</surname><given-names>KX</given-names></name>, <name><surname>Teo</surname><given-names>KYC</given-names></name>, <name><surname>Cheung</surname><given-names>GCM</given-names></name>. <article-title>Influence of pigment epithelial detachment on visual acuity in neovascular age-related macular degeneration</article-title>. <source>Surv Ophthalmol</source>. <year>2020</year>;<volume>66</volume>(<issue>1</issue>):<fpage>68</fpage>–<lpage>97</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.survophthal.2020.05.003</pub-id>
<?supplied-pmid 32428539?><pub-id pub-id-type="pmid">32428539</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
